fexinidazole, trypanosoma brucei rhodesiense, human African trypanosomiasis, clinical trial, Malawi, Uganda, efficacy, safety
fexinidazole, phase IIIb, Democratic Republic of Congo, Guinea, trypanosomiasis, g-HAT, outpatient, Pregnant and breastfeeding women, children